Having often dealt with binder-limited projects, we sought a more accessible source for nanobodies than yeast display or llama. Here we introduce Germinal, computationally designing antibody-like binders with such a hit rate that only tens need to be screened for each target.
The ability to design antibodies against any protein of interest has major implications for medicine, biotech, and basic science.
Today, we introduce Germinal, a pipeline for epitope-targeted de novo antibody design achieving 4–22% success rates with efficient experimental validation.